Stable aqueous anti-vascular endothelial growth factor (vegf) antibody formulation

An aqueous formulation comprising:

• about 15 mg/ml to about 200 mg/ml of an anti-vascular endothelial growth factor (VEGF) antibody;
• about 1 mM to about 100 mM of a buffer;
• about 1 mg/mL to about 300 mg/mL of a polyol;
• about 0.01 mg/ml to about 10 mg/ml of a surfactant;
• about 0.001 mg/ml to about 1.0 mg/ml of a chelating agent;
• and
• wherein the formulation has a pH at about 5.0 to about 6.0.

An aqueous formulation comprising:

• about 15 mg/ml to about 150 mg/ml of an anti-vascular endothelial growth factor (VEGF) antibody;
• about 1 mM to about 100 mM of a buffer;
• about 1 mg/mL to about 300 mg/mL of a polyol;
• about 0.01 mg/ml to about 10 mg/ml of a surfactant;
• about 0.01 mg/ml to about 1.0 mg/ml of a chelating agent;
• wherein the formulation has a pH at about 5.0 to about 6.0;
• and wherein the antibody comprises a heavy chain variable region (VH) complementary determining region one (CDR1) having the amino acid sequence shown in SEQ ID NO:
• 1, a VH CDR2 having the amino acid sequence shown in SEQ ID NO:
• 2, a VH CDR3 having the amino acid sequence shown in SEQ ID NO:
• 3, and a light chain variable region (VL) CDR1 having the amino acid sequence shown in SEQ ID NO:
• 4, a VL CDR2 having the amino acid sequence shown in SEQ ID NO:
• 5, and a VL CDR3 having the amino acid sequence shown in SEQ ID NO:
• 6.

An aqueous formulation comprising:

• about 25 mg/ml of an anti-vascular endothelial growth factor (VEGF) antibody;
• about 20 mM histidine or succinate buffer;
• about 85 mg/mL sucrose;
• about 0.2 mg/ml polysorbate 80;
• about 0.05 mg/ml EDTA;
• wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:
• 7, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:
• 8;
• and
• wherein the formulation has pH at about 5.5 or 5.8.